Anaplastic thyroid carcinoma ranges from 1.3 to 9.8% of all thyroid cancers globally.
Mutations, amplifications, activation of oncogenes and silencing of tumour suppressor genes …

The nuclear factor κB or NF-κB transcription factor family plays a key role in several cellular
functions, ie inflammation, apoptosis, cell survival, proliferation, angiogenesis, and innate …

In multiple myeloma (MM), an incurable B cell neoplasm, mutation or deletion of p53 is
rarely detected at diagnosis. Using small-molecule inhibitors of MDM2, we provide evidence …

Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-
genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. A series …

Abstract p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A
breakthrough in cancer research came from the discovery of the drugs which are capable of …

Three proteasome inhibitors have garnered regulatory approvals in various multiple
myeloma settings; but drug resistance is an emerging challenge, prompting interest in …

The tumor suppressor p53 plays a central role in anti-tumorigenesis and cancer therapy. It
has been described as “the guardian of the genome”, because it is essential for conserving …

Recent advances in the development and discovery of pharmacological interventions within
the ubiquitin–proteasome system (UPS) have uncovered an enormous potential for possible …

Multiple myeloma (MM) is a hematological malignancy characterized by the accumulation of
plasma cells in the bone marrow (BM). The success of the proteasome inhibitor bortezomib …

MicroRNA have been demonstrated to be deregulated in multiple myeloma. We have
previously reported that miR-214 is down-regulated in multiple myeloma compared to in …